Functional polymorphism located in MMP-9 gene promoter is strongly associated with obesity

DNA and Cell Biology

Volumn 31, Issue 6, 2012, Pages 1054-1057

  Andrade, Vanessa L ^a   Fernandes, Karla Simone ^a   Bosco, Adriana Ap ^a   Tanus Santos, José Eduardo ^b   Sandrim, Valeria Cristina ^a  

^a Núcleo de Pós Graduação e Pesquisa Santa Casa de Belo Horizonte   (Brazil)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

GELATINASE B; TISSUE INHIBITOR OF METALLOPROTEINASE 1;

ADULT; ARTICLE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; LEAN BODY WEIGHT; MAJOR CLINICAL STUDY; OBESITY; PRIORITY JOURNAL; PROMOTER REGION;

ADULT; FEMALE; GENE FREQUENCY; GENOTYPE; HUMANS; MATRIX METALLOPROTEINASE 9; OBESITY; POLYMORPHISM, SINGLE NUCLEOTIDE; PROMOTER REGIONS, GENETIC;

EID: 84864062856     PISSN: 10445498     EISSN: 15577430     Source Type: Journal    
DOI: 10.1089/dna.2011.1526     Document Type: Article

References (20)

1. Belo, V.A., Souza-Costa, D.C., Luizon, M.R., Lanna, C.M., Carneiro, P.C., Izidoro-Toledo, T.C., et al. (2012). Matrix metalloproteinase- 9 genetic variations affect MMP-9 levels in obese children. Int J Obes (Lond) 36, 69-75.
2. Bergers, G., Brekken, R., McMahon, G., Vu, T.H., Itoh, T., Tamaki, K., et al. (2000). Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat Cell Biol 2, 737-744.
3. Bouloumie, A., Sengenes, C., Portolan, G., Galitzky, J., and Lafontan, M. (2001). Adipocyte produces matrix metalloproteinases 2 and 9: involvement in adipose differentiation. Diabetes 50, 2080-2086.
4. Garvin, P., Nilsson, L., Carstensen, J., Jonasson, L., and Kristenson, M. (2008). Circulating matrix metalloproteinase-9 is associated with cardiovascular risk factors in a middle-aged normal population. PLoS One 3, e1774.
5. Gerlach, R.F., Meschiari, C.A., Marcaccini, A.M., Palei, A.C., Sandrim, V.C., Cavalli, R.C., et al. (2009). Positive correlations between serum and plasma matrix metalloproteinase (MMP)- 2 or MMP-9 levels in disease conditions. Clin Chem Lab Med 47, 888-891.
6. Goncalves, F.M., Jacob-Ferreira, A.L., Gomes, V.A., Casella- Filho, A., Chagas, A.C., Marcaccini, A.M., et al. (2009). Increased circulating levels of matrix metalloproteinase (MMP)-8, MMP-9, and pro-inflammatory markers in patients with metabolic syndrome. Clin Chim Acta 403, 173-177.
7. Halberg, N., Wernstedt-Asterholm, I., and Scherer, P.E. (2008). The adipocyte as an endocrine cell. Endocrinol Metab Clin North Am 37, 753-768, x-xi.
8. Jacob-Ferreira, A.L., Palei, A.C., Cau, S.B., Moreno, H., Jr., Martinez, M.L., Izidoro-Toledo, T.C., et al. (2010). Evidence for the involvement of matrix metalloproteinases in the cardiovascular effects produced by nicotine. Eur J Pharmacol 627, 216-222.
9. Kenchaiah, S., Evans, J.C., Levy, D., Wilson, P.W., Benjamin, E.J., Larson, M.G., et al. (2002). Obesity and the risk of heart failure. N Engl J Med 347, 305-313.
10. Lacchini, R., Metzger, I.F., Luizon, M., Ishizawa, M., and Tanus- Santos, J.E. (2010a). Interethnic differences in the distribution of matrix metalloproteinases genetic polymorphisms are consistent with interethnic differences in disease prevalence. DNA Cell Biol 29, 649-655.
11. Lacchini, R., Silva, P.S., and Tanus-Santos, J.E. (2010b). A pharmacogenetics- based approach to reduce cardiovascular mortality with the prophylactic use of statins. Basic Clin Pharmacol Toxicol 106, 357-361.
12. Laimer, M., Kaser, S., Kranebitter, M., Sandhofer, A., Muhlmann, G., Schwelberger, H., et al. (2005). Effect of pronounced weight loss on the nontraditional cardiovascular risk marker matrix metalloproteinase-9 in middle-aged morbidly obese women. Int J Obes 29, 498-501.
13. Loftus, I.M., Naylor, A.R., Goodall, S., Crowther, M., Jones, L., Bell, P.R., et al. (2000). Increased matrix metalloproteinase-9 activity in unstable carotid plaques. A potential role in acute plaque disruption. Stroke 31, 40-47.
14. Mun-Bryce, S., and Rosenberg, G.A. (1998). Matrix metalloproteinases in cerebrovascular disease. J Cereb Blood Flow Metab 18, 1163-1172.
15. Mun-Bryce, S., Wilkerson, A., Pacheco, B., Zhang, T., Rai, S., Wang, Y., et al. (2004). Depressed cortical excitability and elevated matrix metalloproteinases in remote brain regions following intracerebral hemorrhage. Brain Res 1026, 227-234.
16. Palei, A.C., Sandrim, V.C., Duarte, G., Cavalli, R.C., Gerlach, R.F., and Tanus-Santos, J.E. (2010). Matrix metalloproteinase (MMP)-9 genotypes and haplotypes in preeclampsia and gestational hypertension. Clin Chim Acta 411, 874-877.
17. Peters, D.G., Kassam, A., St. Jean, P.L., Yonas, H., and Ferrell, R.E. (1999). Functional polymorphism in the matrix metalloproteinase- 9 promoter as a potential risk factor for intracranial aneurysm. Stroke 30, 2612-2616.
18. Pollanen, P.J., Karhunen, P.J., Mikkelsson, J., Laippala, P., Perola, M., Penttila, A., et al. (2001). Coronary artery complicated lesion area is related to functional polymorphism of matrix metalloproteinase 9 gene: an autopsy study. Arterioscler Thromb Vasc Biol 21, 1446-1450.
19. Silha, J.V., Krsek, M., Sucharda, P., and Murphy, L.J. (2005). Angiogenic factors are elevated in overweight and obese individuals. Int J Obes 29, 1308-1314.
20. Zhang, B., Ye, S., Herrmann, S.M., Eriksson, P., de Maat, M., Evans, A., et al. (1999). Functional polymorphism in the regulatory region of gelatinase B gene in relation to severity of coronary atherosclerosis. Circulation 99, 1788-1794.